I Founded a Health Technology Company — Here's Why
When my son was diagnosed with Type 1 diabetes as a 3-year-old, our family's world changed overnight. But what surprised me most wasn't the diagnosis itself — it was that the systems around us didn't talk to each other.
The CGM sensor sent data to one app. The doctor used another. The kindergarten got a laminated sheet. And we — the parents — sat in the middle trying to keep track of everything. There was no reason it had to be that way.
I spent weeks navigating between different platforms, manually copying numbers from one screen to another, texting blood sugar readings to kindergarten staff who had no medical training and no idea what to do with them. Every handoff was a potential point of failure. And for a 3-year-old who can't tell you when something feels wrong, that failure isn't abstract — it's dangerous.
So I built what was missing.
What is Luca MedTech?
Luca MedTech is a health technology company I founded in February 2026, based in Oslo. We build digital tools that make daily life easier for families living with Type 1 diabetes.
Our main product is DiaLuca — three modules, one application:
- DiaLuca Familie: For families and caregivers. A shared dashboard where parents, grandparents, and other caregivers all see the same real-time data — glucose levels, insulin doses, meal logs, and alerts. No more calling to ask "what was the last reading?" Always free.
- DiaLuca Assistent: For kindergarten, school, and after-school staff without medical background. A traffic light system (green/yellow/red) with simple action instructions. When the light is green, everything is fine. Yellow means check in. Red means act now — and the app tells you exactly what to do. No medical degree required.
- DiaLuca Klinikk: A digital onboarding tool for newly diagnosed T1D patients and families at the hospital. Instead of being handed a stack of brochures during the most overwhelming week of your life, families get a structured, step-by-step digital guide they can revisit at their own pace.
DiaBridge — Connecting the Data That Matters
We're also building DiaBridge — automatic data flow from CGM sensors directly into DIPS, the Norwegian hospital journal system.
Today, when a doctor wants to see a patient's CGM data before a consultation, that data lives in a separate manufacturer app — Dexcom Clarity, LibreView, or CareLink. The doctor has to log in separately, or the patient has to bring a printout. DiaBridge eliminates that gap entirely. CGM readings flow automatically into the patient's hospital record, so the clinician sees the full picture in one place, in real time.
No manual work. No printouts. No data trapped in silos. DiaBridge integrates with DIPS, Helsenorge, HelseID, Noklus Diabetes, Dexcom, Medtronic, Abbott, and more.
Norwegian Health Tech on Norwegian Terms
From day one, we made a deliberate choice: all patient data is stored on Norwegian servers. No American cloud services. No CLOUD Act exposure. No foreign jurisdiction over Norwegian patient data.
What does that mean in practice? The U.S. CLOUD Act allows American authorities to demand data from U.S.-based cloud providers — even if the servers are in Europe. By choosing Norwegian-only infrastructure, we ensure that Norwegian privacy law is the only law that applies to our patients' data. Full stop.
This isn't just a technical decision — it's a trust decision. When families share their child's health data, they need to know exactly where that data lives and who can access it. We built to Normen and Norwegian privacy law from the start. The patient always has full control over who sees their data.
What's Next
We're currently seeking pilot hospitals, municipalities, and families who want to test the platform early. If you work in pediatric diabetes care, run a kindergarten with T1D children, or are a family living with Type 1 diabetes — I'd love to hear from you.
You can reach me through the contact page or visit lucamedtech.no to learn more.
After more than a decade building companies in digital media and fintech, this is the most personal venture I've ever started. It didn't come from a market analysis or a business plan — it came from sitting on a hospital floor at 3 AM, trying to understand a glucose curve on a phone screen, knowing there had to be a better way.
There is. And we're building it.